-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SKP-0160 in Hemostasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SKP-0160 in Hemostasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SKP-0160 in Hemostasis Drug Details: SKP-0160 is under development for treatment of hemostasis....
-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Infion/ SK Plasma – Jakarta Blood Plasma Fractionation Facility – Jakarta
Equip yourself with the essential tools needed to make informed and profitable decisions with our Infion/ SK Plasma - Jakarta Blood Plasma Fractionation Facility - Jakarta report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Its treatment includes replacing the defective clotting factor. The Hemophilia B pipeline market research report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...